|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM295069228 |
| 003 |
DE-627 |
| 005 |
20231225082844.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201808303
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0983.xml
|
| 035 |
|
|
|a (DE-627)NLM295069228
|
| 035 |
|
|
|a (NLM)30883982
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ovais, Muhammad
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.11.2019
|
| 500 |
|
|
|a Date Revised 30.09.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Advances in the field of nanotechnology together with an increase understanding of tumor immunology have paved the way for the development of more personalized cancer immuno-nanomedicines. Nanovehicles, due to their specific physicochemical properties, are emerging as key translational moieties in tackling tumor-promoting, M2-like tumor-associated macrophages (TAMs). Cancer immuno-nanomedicines target TAMs primarily by blocking M2-like TAM survival or affecting their signaling cascades, restricting macrophage recruitment to tumors and re-educating tumor-promoting M2-like TAMs to the tumoricidal, M1-like phenotype. Here, the TAM effector mechanisms and strategies for targeting TAMs are summarized, followed by a focus on the mechanistic considerations in the development of novel immuno-nanomedicines. Furthermore, imaging TAMs with nanoparticles so as to forecast a patient's clinical outcome, describing treatment options, and observing therapy responses is also discussed. At present, strategies that target TAMs are being investigated not only at the basic research level but also in early clinical trials. The significance of TAM-targeting biomaterials is highlighted, with the goal of facilitating future clinical translation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a biomaterials
|
| 650 |
|
4 |
|a cancer immuno-nanomedicine
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a nanocarriers
|
| 650 |
|
4 |
|a tumor-associated macrophages
|
| 650 |
|
7 |
|a Biomarkers, Tumor
|2 NLM
|
| 700 |
1 |
|
|a Guo, Mengyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Chunying
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 31(2019), 19 vom: 07. Mai, Seite e1808303
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:2019
|g number:19
|g day:07
|g month:05
|g pages:e1808303
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201808303
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 2019
|e 19
|b 07
|c 05
|h e1808303
|